The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.
SBC: BIOPROTECTION SYSTEMS CORP. Topic: CBD08105
The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift Valley fever virus (RVFV, bunyavirus), and Lassa virus (LV, arenavirus), to evaluate the adjuvant pot ...SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense